Get the Stockscreener App
2.39
10.14%
0.22
Pre-market:
2.19
-0.20
-8.37%
Creative Medical Technology Holdings Inc stock is traded at $2.39, with a volume of 81,790.
It is up +10.14% in the last 24 hours and up +6.70% over the past month.
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.
See More
Previous Close:
$2.17
Open:
$2.2
24h Volume:
81,790
Relative Volume:
1.44
Market Cap:
$8.84M
Revenue:
$3,000
Net Income/Loss:
$-5.76M
P/E Ratio:
-1.2939
EPS:
-1.8471
Net Cash Flow:
$-5.59M
1W Performance:
+10.17%
1M Performance:
+6.70%
6M Performance:
+12.74%
1Y Performance:
+9.63%
1-Day Range:
$2.11
$2.39
1-Week Range:
$2.07
$2.39
52-Week Range:
$1.504
$6.25
Creative Medical Technology Holdings Inc Stock (CELZ) Company Profile
Name
Creative Medical Technology Holdings Inc
Sector
Industry
Phone
480-399-2822
Address
211 E. OSBORN RD., PHOENIX
Compare CELZ vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELZ
Creative Medical Technology Holdings Inc
|
2.39 | 8.84M | 3,000 | -5.76M | -5.59M | -1.8471 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Creative Medical Technology Holdings Inc Stock (CELZ) Latest News
12 Health Care Stocks Moving In Monday's After-Market SessionAlvotech (NASDAQ:ALVO), Anixa Biosciences - Benzinga
CELZ Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift SharesFull Year Guidance - newsline.com
Anthropic Quietly Releases Claude Fable 5 to Public After Earlier ConcernsPreliminary Results - newsline.com
Hancock Whitney Q1 2026 Earnings: EPS Beats Estimates Modestly Amid Flat Revenue EnvironmentOperating Margin Analysis - newsline.com
CELZ Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive SentimentEarnings Revision Report - newsline.com
Spain Tourism Surges to Record as Travelers Shift from Middle EastShort-Term Outlook - newsline.com
Pro-Dex Inc. (PDEX) Edges Higher as Shares Trade Near ResistanceHedge Fund Favorites - newsline.com
CELZ Q1 2026 Earnings: Loss Per Share Narrows, Topping Analyst EstimatesEarnings Revision Downgrade - The Legal Advocate
CELZ Q1 2026 Earnings: Narrower Q1 Loss Fails to Lift Shares as Market Focuses on Cash RunwayFinancial Health Score - newsline.com
CELZ PE Ratio & Valuation, Is CELZ Overvalued - Intellectia AI
EPS Creative Health Technology Group Limited Announces Management Changes, Effective May 31, 2026 - marketscreener.com
Creative Medical Technology (CELZ) Edges Lower by 0.22% as Stock Consolidates Between Key LevelsStock Surge Alerts - The Legal Advocate
MFA Financial Inc. 8.875% Senior Notes due 2029 (MFAN) Q1 2026 Earnings: EPS Falls Just Short of Estimates, Bond Price Edges HigherProfit Cycle Analysis - The Legal Advocate
MIRA Pharmaceuticals Inc. (MIRA) Slips 8.66% to $1.05 as Technicals Test Key SupportLinear Regression - newsline.com
CELZ Q1 2026 Earnings: Narrower-Than-Expected Loss as Pipeline AdvancesProfit Guidance Range - The Legal Advocate
Critical Metals Corp (CRML) Slips 3.75% as Key Support Level Tests BuyersRSI Oversold Picks - The Legal Advocate
CELZ Stock Price, Quote & Chart | CREATIVE MEDICAL TECHNOLOGY (NASDAQ:CELZ) - ChartMill
Intercontinental Exchange (ICE) Edges Higher Amid Positive Volume TrendsLast Point Support - newsline.com
Creo Medical shares surge 27% on proposed sale of remaining European stake - Yahoo Finance
Japan Smaller Capitalization Fund (JOF) Edges Lower Amid Modest PullbackMAMA Signal - The Legal Advocate
Creative Medical Technology Holdings, Inc.Common Stock (NQ: CELZ - FinancialContent
Accel Entertainment (ACEL) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
Xtant Medical Q1 2026 Results: Revenue Guidance Raised, Balance Sheet Strengthened, Exclusive HEMOBLAST® Bellows Distribution Secured 12 - Minichart
QT Imaging Reports First Quarter 2026 Revenue of $6.5 Million - Business Wire
Incannex Healthcare Wins MedTech Breakthrough Award for Innovative Obstructive Sleep Apnea Drug IHL-42X - Minichart
Leading Breast Surgical Oncologist Dr. Barry Roseman to Serve as Senior Medical Advisor to QT Imaging - Business Wire
United States shares higher at close of trade; Dow Jones Industrial Average up 0.19% - Investing.com India
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.19% - Investing.com
CELZ (CreativeMed) EPS beats estimates but shares fall nearly 3% despite narrower losses.AI Stock Signals - Newser
Creative Medical Technology Holdings Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Creative Medical Technology Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Creative Medical Technology (NASDAQ: CELZ) posts Q1 2026 loss, details cash use - Stock Titan
How CreativeMed (CELZ) prepares for market disruptions | Q3 2025: Earnings Beat EstimatesTrend Analysis - newser.com
Governor Newsom announces $1B in private investment generated through California Competes Tax Credits, driving business expansion in key industry sectors - California State Portal | CA.gov
Creative Medical Technology Holdings Inc expected to post a loss of 39 cents a shareEarnings Preview - TradingView
CVRx (CVRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
Theradaptive Secures FDA Approval to Advance OASIS Trial to Pivotal Study Evaluating OsteoAdapt® SP in Spinal Fusion - Yahoo Finance
Roth MKM Maintains Creative Medical Technology(CELZ.US) With Buy Rating, Maintains Target Price $20 - Moomoo
BZLEY Should I Buy - Intellectia AI
Creative Medical (CELZ) Reports Encouraging Pilot Study Results for Ultrasome Therapy - GuruFocus
Creative Medical (CELZ) Reports Promising Osteoarthritis Therapy Results - GuruFocus
BY Technical Analysis & Price Forecast - Intellectia AI
Creative Medical reports positive pilot study results for Ultrasome - Investing.com UK
Creative Medical reports positive pilot study results for Ultrasome By Investing.com - Investing.com Australia
Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome™ Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies - The Manila Times
Park Place Technologies Partners with Professional Athlete Genie Bouchard as 'Genie from IT” in New TV Commercial - The Manila Times
Uncertainty Around AI’s Impact on Careers Clouds Students’ College Decisions - The Manila Times
Cell-free knee arthritis therapy posts 93% response in pilot study - Stock Titan
Multiple BottomStock ScreenerCharts - Finviz
JXHLY Forecast — Price Prediction for 2026. Should I Buy JXHLY? - Intellectia AI
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
Creative Medical Technology Holdings Inc Stock (CELZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):